temozolomide + tamoxifen + maprotiline

This drug is a combination therapy consisting of three agents used primarily in the treatment of recurrent glioblastoma, a highly aggressive brain tumor. - **Temozolomide** is an oral alkylating agent that kills cancer cells by damaging their DNA through alkylation, preventing cell division and inducing cell death. It is considered the standard chemotherapy for glioblastoma. - **Tamoxifen** is an anti-estrogen molecule known to inhibit protein kinase C (PKC) independently of estrogen receptor pathways. It has antineoplastic effects and can potentiate temozolomide's efficacy by synergistically increasing apoptosis and reducing proliferation in glioma cells. - **Maprotiline** is a tetracyclic antidepressant with norepinephrine reuptake inhibition properties, used here off-label as part of combination therapy for its potential to enhance treatment effects in glioblastoma. The combination aims to overcome chemoresistance seen in glioblastoma by targeting multiple pathways simultaneously. Clinical studies have explored this triple regimen for recurrent glioblastoma with some indication of tolerability and potential efficacy, though maprotiline’s role remains investigational.